Recruiting NCT04499755
Efficacy of Nucleo CMP Forte in Traumatic Brain Injury in Pediatrics
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Nucleo CMP Forte.
- Who it may be relevant to
- Registry conditions: Brain Injuries. Basic parameters: up to 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Efficacy of Nucleo CMP Forte in Traumatic Brain Injury in Pediatrics: A Randomized Controlled Trial
Overview
Efficacy of Nucleo CMP Forte in Traumatic Brain Injury in Pediatrics
Detailed description
The study aims to study the Efficacy of Nucleo CMP Forte in Traumatic Brain Injury in Pediatrics
Interventions
- Drug Nucleo CMP Forte
Nucleo CMP Forte twice daily for 6 weeks
Primary outcome measures
- Number of patients with improved glasgow coma score [Time frame: 2 months]
Eligibility criteria
Inclusion criteria
- Children with traumatic brain injury: Moderate and Severe.
Exclusion criteria
- Underlying CNS disorders,
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Triple blind
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Sherief Abd-Elsalam — Tanta
Identifiers
NCT: NCT04499755 · KFS protocol